Context: Small papillary thyroid cancer (PTC) generally has an excellent prognosis. However, longterm recurrence is not uncommon and sometimes leads to morbidity or mortality.
T hyroid cancer is the most common malignancy in Korea. According to the statistics of the Korea Central Cancer Registry, 44,007 thyroid cancer cases accounting for 19 .6% of all malignancies were recorded in 2012 (1) . The estimated age-standardized incidence rate of thyroid cancer was 62.5 per 100,000 people (23.0 and 102.4 per 100,000 people for men and women, respectively), which was the highest in the world according to the GLOBOCAN 2012 database of the International Agency for Research on Cancer/World Health Organization (http://globocan.iarc.fr). The rapid rise in the incidence of thyroid cancer has been attributed mainly to the increase in the incidence rate of small papillary thyroid cancer (PTC), particularly papillary thyroid microcarcinoma (PTMC). PTMC, which is defined by a tumor diameter of #10 mm, accounted for more than half of all PTC in the last decades (2) .
Although patients with small PTC generally have an excellent prognosis with low recurrence rates, locoregional recurrence and distant metastasis have been reported in disease subsets, which could lead to disease-related mortality as well as decreased quality of life (3, 4) . Total thyroidectomy followed by radioactive iodine (RAI) ablation and thyroid-stimulating hormone (TSH) suppression therapy using levothyroxine has been traditionally considered the appropriate treatment strategy for decreasing recurrence rate and disease-specific mortality in patients with PTC (5) . Recently, the trend has shifted toward the use of more conservative treatment strategies, particularly for low-risk PTC. The 2015 American Thyroid Association management guidelines for thyroid cancer suggested that lobectomy might be a sufficient treatment option for low-risk PTCs of 1 to 4 cm in size as well as for unifocal, intrathyroidal PTMCs and that thyroidectomy without prophylactic central neck dissection is possibly a suitable treatment option for small (#2 cm), noninvasive, clinically node-negative PTC (6) . However, because of the absence of high-quality studies justifying the use of these management strategies, the optimal treatment strategy for small PTC is still controversial.
Previous studies suggested that several clinicopathologic characteristics, including old age, male sex, extrathyroidal tumor extension, and lymph node (LN) metastasis, were risk factors for recurrence in patients with PTC (7, 8) . LN metastasis and distant metastasis at the time of diagnosis are concrete risk factors for recurrence; however, the evidence for other probable risk factors such as male sex, old age, multifocality, bilaterality, and minimal extrathyroidal extension has been inconclusive. In addition, total thyroidectomy was thought to be associated with a lower risk of locoregional recurrence (9), albeit overall survival or disease-specific survival did not differ between patients who underwent total thyroidectomy and thyroid lobectomy (10) (11) (12) . Adjuvant RAI therapy after total thyroidectomy has been used to minimize the risk of disease recurrence. However, the additional advantage conferred by RAI on the reduction of recurrence in intermediaterisk patients with PTC has been controversial because of the lack of prospective controlled trials (6) .
Although a more detailed risk stratification system has been provided in the new guidelines, it appears that the controversy surrounding risk factors for recurrence of small PTC will persist. Thus, more precise evaluation of the risk of recurrence is warranted for personalized decisions regarding initial treatment, which varies from observation without surgical therapy to total thyroidectomy with RAI (13) (14) (15) .
We conducted a nationwide, retrospective, multicenter study involving 3282 patients with small PTCs (size, #2 cm) from 9 high-volume hospitals to identify the risk factors for disease recurrence.
Materials and Methods
We retrospectively reviewed thyroid cancer patients who underwent surgical treatment at 9 hospitals in Korea between January 2000 and December 2004. Patients who were pathologically diagnosed with PTC measuring #2 cm were included in the study. We initially screened 3574 patients with PTC #2 cm. Fifty-three (1.5%) patients with initial distant metastasis were excluded. In this study, we defined structurally identified disease during postoperative year 1 as persistent disease or initially metastatic disease, and considered newly discovered disease after postoperative year 1 as a recurrence. Therefore, 26 (0.7%) patients who showed persistent diseases were excluded, and 213 patients whose follow-up duration was ,1 year were also excluded. Finally, we reviewed the medical records of 3282 eligible patients for the assessment of age, sex, tumor size, bilaterality, multifocality, extrathyroidal tumor extension, LN metastasis, surgical extent, and RAI ablation therapy. Data on pathologic features were collected from the initial pathology reports. Recurrence was diagnosed on the basis of pathologic specimens or imaging studies including neck ultrasonography, diagnostic iodine-131 whole-body scan, chest radiography, computed tomography, positron emission tomography, or bone scan. This study was approved by the institutional review boards of the participating hospitals.
Statistical analysis
All data were analyzed using STATA software version 13.0 (StataCorp, College Station, TX). The descriptive variables were expressed as mean 6 SD. Patient characteristics were compared using the Pearson x 2 test and Student t test. To select the appropriate cutoff tumor size, the number of metastatic LNs, and the LN ratio (LNR; the number of metastatic LNs/the number of dissected LNs provided that the number of dissected LNs was $5) that best predicted PTC recurrence, maximally selected x 2 statistics were adapted (R Software version 3.0.2; R Foundation for Statistical Computing, Vienna, Austria).
The probable risk factors for recurrence included old age (.45 years), male sex, large tumor size, multifocality, extrathyroidal extension, and LN metastasis (stage N1, number of metastatic LNs, and LNR) for all patients. The extent of surgical resection was divided into 2 groups: the total thyroidectomy group (total, near-total, or subtotal thyroidectomy) and the lobectomy group. Completion thyroidectomy following lobectomy was regarded as total thyroidectomy.
To identify additional risk factors associated with recurrence in the total thyroidectomy group, we selected a subgroup of 2839 patients who underwent total thyroidectomy. Tumor bilaterality and not being subjected to RAI therapy were assumed to be additional probable risk factors for recurrence in patients treated with total thyroidectomy because bilaterality could not be assessed in cases of lobectomy and only patients who underwent total thyroidectomy could receive RAI therapy. Univariate analysis was performed on additional prognostic factors including bilaterality and RAI ablation therapy. Multivariate recurrence analysis was conducted to assess independent risk factors including both RAI ablation and bilateral tumor. Additionally, recurrence analysis was performed in 443 patients who underwent lobectomy.
The Kaplan-Meier method was used to generate the recurrence curves. Univariate and multivariate analyses were performed using the Cox regression model. A P value ,0.05 was considered statistically significant.
Results

Clinicopathologic characteristics
The mean follow-up duration was 5.8 years (range, 1.0 to 10.2 years). The mean age at diagnosis was 47 years, and 88.3% of the patients were female. The mean tumor size was 1.1 cm (range, 0.1 to 2.0 cm). Eighty-six percent of the patients were treated with a total, near-total, or subtotal thyroidectomy (the total thyroidectomy group), and 77.4% of the patients in the total thyroidectomy group underwent RAI ablation therapy. We compared the clinicopathologic parameters of patients classified by the extent of surgical resection. Patients in the total thyroidectomy group were older than patients in the lobectomy group (47 vs 44 years, respectively; P , 0.001). Central neck dissection and modified radical neck dissection were more frequently performed in the total thyroidectomy group than in the lobectomy group. In addition, tumors in the total thyroidectomy group were larger than those in the lobectomy group (1.1 vs 0.9 cm, respectively; P , 0.001). The rate of tumor multifocality, extrathyroidal extension, and LN metastasis were also significantly higher in patients who underwent total thyroidectomy than in those who underwent lobectomy ( Table 1 ).
The optimal cutoff values for tumor size, number of metastatic lymph nodes, and lymph node ratio for predicting recurrence
We divided the patients into 2 groups on the basis of tumor size from 0.7 to 1.9 cm with 0.1-cm intervals (0.7, 0.8, … or 1.9 cm) and compared the recurrence rates between each of the 2 groups. The optimal tumor size cutoff for predicting the risk of recurrence was 1.8 cm. We evaluated the prognostic impact of the number of metastatic LNs and the LNR. A clear difference was observed between the recurrence rates of patients who had 0 or 1 metastatic LN and those who had $2 metastatic LNs. An LNR of 0.19 was the optimal cutoff value for predicting the risk of recurrence. The median number press.endocrine.org/journal/jcemof dissected LNs used for the determination of LNR was 9. The 5-and 10-year recurrence rates for crude cutoff are detailed in Supplemental Table 1 .
Prognostic factors for recurrent disease
Within the follow-up period, 190 patients showed disease recurrence. The 5-and 10-year recurrence rates were 4.5% and 8.9%, respectively. For patients who underwent total thyroidectomy, the 5-and 10-year recurrence rates were 4.4% and 7.5%, respectively; and for those who underwent lobectomy, they were 5.5% and 18.3%, respectively (Fig. 1) .
The LNs in the neck were the most common sites of recurrence (121 cases; 64%), followed by the thyroid bed (55 cases) and the lungs (3 cases). The sites of recurrence in the remaining 11 patients were unidentified. Twentyfive percent (39 cases) of the recurrences in the total thyroidectomy group occurred in the thyroid bed, whereas 43% (16 cases) of the recurrences in the lobectomy group occurred in the thyroid bed or the remnant thyroid.
We investigated the prognostic factors associated with recurrence in all PTC patients ( Fig. 1 
and the number of metastatic LNs (HR, 4.32; 95% CI, 2.42 to 7.71; P , 0.001); however, it was not a statistically significant factor in models based on LNR (HR, 3.36; 95% CI, 0.80 to 14.06; P = 0.098). The recurrence rates did not differ between the total thyroidectomy and lobectomy groups for a follow-up duration of 5 years (log-rank, P = 0.379). However, the gap between the recurrence rate curves widened after 5 years (Fig. 1F) .
In patients who underwent total thyroidectomy, univariate analysis showed that male sex, tumor size $1.8 cm, Recurrence rates were calculated using Kaplan-Meier methods, and P values were calculated using log-rank tests. TT, total thyroidectomy; LT; lobectomy.
LN metastasis, bilaterality, and RAI ablation were significantly associated with cancer recurrence (Supplemental Table 2 ). Multivariate analysis showed that tumor size $1.8 cm, bilaterality, and LN metastasis remained significantly related to increased recurrence in the models based on the number of metastatic LNs and LNR. However, RAI ablation did not show significance in multivariate analysis. The recurrence rates in patients who underwent total thyroidectomy according to risk factors are shown in Fig. 2 (A-F) .
In patients with PTC who underwent lobectomy, multifocality and LN metastasis (N stage and number of metastatic LNs) were prognostic factors for recurrence; however, tumor size was not a risk factor. Multivariate analysis of models based on N stage and the number of metastatic LNs confirmed that multifocality and LN metastasis were risk factors for recurrence (Supplemental Table 3 ). The recurrence rate curves according to risk factors are shown in Fig. 3 (A-C) .
Discussion
PTC has a low mortality rate; however, locoregional recurrence is common even in patients with small PTC (4). To date, the prognostic factors that predict recurrence in patients with PTC have not been clearly defined because of ongoing changes in the clinical features and therapeutic strategies for thyroid cancer over the decades. Furthermore, treatment approaches are not uniform across all institutions. Therefore, we aimed to identify risk factors for recurrence in small PTC patients using a large-scale multicenter study. In the current study, 5-and 10-year recurrence rates for all PTC patients were 4.4% and 7.5%, respectively. Bilimoria et al. (16) reported that the recurrence rates in large national cancer data were 5.7% at 5 years and 9.4% at 10 years, similar to our data.
In this study, recurrence rates significantly differed between patients who underwent total thyroidectomy and those who underwent lobectomy. In the 1990s, several studies reported the advantages of total thyroidectomy for PTC (5, 7). Thus, total thyroidectomy has been the preferred method of surgical treatment even for small PTC. Our data showed that only 13.5% of PTC patients with tumors 0.1 to 2.0 cm in size underwent lobectomy, which is one of the independent prognostic factors for recurrent disease. Because LN metastasis is the most important risk factor for tumor recurrence in PTC, ineffective removal of nodal metastases could be the main cause of recurrence in patients who underwent lobectomy. Undetected bilateral tumors or metachronous tumors that remained in the contralateral lobe after lobectomy could be another cause of recurrence. These possible causes might contribute to statistically significant differences in recurrence based on the extent of surgical intervention. Total thyroidectomy was thought to reduce the risk of recurrence even in patients with small PTC (17) . However, the 2015 American Thyroid Association guidelines recommend thyroid lobectomy as the optimal treatment of small, unifocal, Recurrence were calculated using Kaplan-Meier methods, and P values were calculated using log-rank tests. Recurrence were calculated using Kaplan-Meier methods, and P values were calculated using log-rank tests.
intrathyroidal PTC in the absence of a history of head and neck irradiation, familial thyroid carcinoma, or clinically involved nodal metastases (6) . These guidelines suggested that recurrence during follow-up could be readily detected and properly managed with no impact on survival. Evidence for these guidelines mostly focused on mortality; however, the actual advantage on the decrease in recurrence risk conferred by total thyroidectomy was not well evaluated in previous studies (Table 3) . According to the current study, total thyroidectomy at initial diagnosis could be considered to circumvent reoperation, particularly in patients receiving thyroid hormone therapy or those with subclinical hypothyroidism. Moreover, complication rates associated with the surgical methods did not differ between lobectomy and total thyroidectomy in Korea (18) . In this cohort, more than 70% of patients in the total thyroidectomy group were treated with RAI. The lower recurrence rate in the total thyroidectomy group could be attributed to use of RAI rather than to the total thyroidectomy itself. We did an additional analysis with patients who underwent total thyroidectomy but no RAI therapy for comparison with those who underwent lobectomy (data not shown). It showed that lobectomy was an independent prognostic factor for recurrence, which suggested that the lower recurrence rate in the total thyroidectomy group may not be attributable to the use of RAI.
LN metastasis at the time of initial surgery is recognized as one of the most important risk factors for the recurrence of PTC (8) . Our data confirmed that N1a and N1b were major independent prognostic factors for predicting the recurrence of small PTC. Furthermore, a metastatic LN number $2 and elevated metastatic LNR $0.19 were also found to be associated with the recurrence of PTC. We suggest that any of the 3 models of LN metastasis could be applied for risk stratification. The optimal cutoff point of LNR that could predict recurrence was 0.19, which was not consistent with the results of previous studies (19) . In addition, Schneider et al. (20) reported that an LNR $0.42 was the optimal value for stratifying PTC patients on the basis of disease-specific mortality. However, the optimal cutoff points for diseasespecific mortality and risk of recurrence could differ. In the current study, patients with an LNR #0.18 showed a 10-year recurrence rate of 2.7%, which might be considered negligible. Therefore, we suggest the use of an LNR threshold of 0.19 for risk stratification in PTC patients. Predicting LN metastasis that cannot be detected via ultrasonography would pose a major challenge in future studies.
Tumor size was traditionally considered a prognostic factor for disease recurrence, and the extent of surgery as well as the application of RAI treatment after surgery are largely determined by tumor size. PTCs were generally divided into PTMC and conventional PTC on the basis of a tumor size of 1.0 cm. PTMCs had significantly lower recurrence rates than PTCs with tumors sized 1.1 to 2.0 cm, as demonstrated by the current study as well as by previous studies (7, 21) . On the other hand, in several studies, the rate of recurrence did not differ between PTMCs and PTCs sized 1.0 to 4.0 cm (4, 22) . Therefore, the feasibility of stratifying patients according to PTMC or PTC .1 cm in size is controversial because a tumor size of 1 cm is an arbitrary value. Moreover, a tumor size .1 cm was less significant than other factors such as lymph node metastasis and the extent of surgical resection for predicting cancer recurrence in patients with small PTC. Thus, distinguishing PTMCs from PTCs on the basis of a tumor size threshold of 1 cm alone did not appear to be effective for predicting recurrence. We found that the optimal tumor size cutoff for predicting the risk of recurrence was 1.8 cm.
Bilaterality and multifocality are common features of PTC and are generally considered poor prognostic factors (23) (24) (25) . In the current study, multivariate analysis showed a significant correlation between tumor bilaterality and tumor recurrence, consistent with the results of a previous study showing that synchronous bilateral PTC had more advanced tumor stage and higher recurrence rate than unilateral PTC (23) . However, we did not identify a difference in recurrence based on multifocality, and this result was inconsistent in relation to previously reported results (14, 21, 26) . According to our data, unilateral multifocality was not a risk factor for recurrence in cases of total thyroidectomy, whereas a multifocal tumor in PTC patients who underwent lobectomy showed high incidence of disease recurrence, which indicated a possible bilateral tumor or lymph node metastasis in patients who underwent lobectomy. A longer follow-up period is warranted to evaluate the impact of multifocality on recurrence. RAI treatment after surgery was previously thought to substantially reduce the risk of recurrence (27) ; however, the possible minimal role of RAI in the treatment of small PTC, particularly PTMC, was indicated recently (3, 28) . Consistent with the latter hypothesis, use of RAI after total thyroidectomy was not an independent factor for recurrence in the multivariate analysis. However, the possibility that patients with other potential risk factors for recurrence underwent RAI treatment on the basis of the physician's decision cannot be discounted. Because of a possible selection bias in the current study, whether RAI treatment had an additional effect on the recurrence of PTC could not be determined. Prospective controlled studies should be conducted to determine whether RAI treatment is beneficial for preventing disease recurrence or improving survival in patients with small PTC.
Male sex has been considered a poor prognostic factor for the recurrence and mortality associated with PTC (29) (30) (31) . However, consistent with some previous reports (4, 14, 32, 33) , no correlation was observed between male sex and disease recurrence in patients with PTC in the current study. Recently, Ito et al. (34) showed that disease-free survival was significantly worse in men, and the male sex was found to be an independent risk factor for mortality of PTMC patients in a large cohort (30) . We did not demonstrate the significance of sex in the recurrence of small PTC.
Advanced age is considered a prognostic factor for the recurrence and survival of PTC patients (29, 30 ). In the current study, old age was not an independent predictor of recurrence in patients with PTC. Numerous studies have reported that advanced age was not associated with tumor recurrence (3, 19, 21, 35) . Moreover, a meta-analysis showed that younger age (,45 years) was associated with recurrence of PTMC (32) . A similar trend was observed in our study. However, most studies focusing on survival analysis demonstrated that old age was associated with PTC-related death (8, 30, 36) . These conflicting findings suggest that the risk of cancer death is not always consistent with that of cancer recurrence. Although small PTC recurs frequently in younger patients after initial treatment, it should be noted that cancer death and tumor recurrence in these cases do not seem to be directly correlated. One possible explanation could be that younger patients are monitored more aggressively to identify recurrence after initial treatment than are older patients, whereas older patients with recurrent PTC might have other potential risk factors associated with cancer-related death.
In the present study, TSH suppression therapy was not assessed as a prognostic factor. TSH suppression therapy is known to be effective in reducing recurrence of PTC and could be a prognostic factor after surgery. However, it was hard to evaluate degrees of TSH suppression and duration of TSH suppression therapy in a retrospective study with long-term observation. Lack of data for TSH suppression could be a limitation of our study.
We conducted a nationwide, retrospective, multicenter study to identify the prognostic factors associated with the recurrence of PTCs #2.0 cm in size. The number of LN metastases $2 at the time of initial surgery, treatment with lobectomy, tumor size $1.8 cm, and bilaterality were independent risk factors for recurrence in PTC patients. In addition, an LNR $0.19 was determined to be the cutoff for higher risk of recurrence. Thus, while the extent of surgical resection is being determined, patients should be carefully examined for LN metastasis or bilateral tumors. For patients with high risk factors, total thyroidectomy could be considered if it is expected to reduce the risk of recurrence for small PTC.
